Neil Clark & Shaun Claydon of Destiny Pharma: Funds raised will be used to accelerate the development of their two lead key assets

Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma #DEST discuss how the £6.7m raised will be used to accelerate the development and finalise regulatory plans for the Phase III trials of their two lead key assets:

NTCD‐M3 is a potential game-changer for the prevention of C. difficile infection (CDI) recurrence, the leading cause of hospital-acquired infection in the US with a potential peak sales opportunity of $0.5 billion. 

XF-73 nasal is being developed for the prevention of post-surgical staphylococcal infections, a $1 billion market opportunity in the US alone. 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.